The NIMML Institute and NImmune Biopharma Announce Publication of New Mechanistic Insights on the Immunometabolic Control of Systemic Lupus Erythematosus in the Journal of Immunology

by NImmune Biopharma | Oct 7, 2024 | Press Release

Download Press Release NIM-1324 validated as the first LANCL2 drug with therapeutic efficacy in systemic inflammation in three mouse models of lupus to support immune tolerance A mechanism of LANCL2 newly discovered in phagocytes that combines with established...

NImmune Biopharma to Participate in UBS Virtual Biotechnology Private Company

by NImmune Biopharma | Sep 16, 2024 | Press Release

Download Press Release BLACKSBURG, VA. – September 16, 2024 – NImmune Biopharma (“NImmune”), a Phase 3 precision inflammation & immunology (I&I) biopharmaceutical company that develops novel best-in-class biomarker-driven immunoregulatory...

The AI Paradigm Shift: How Cutting-Edge Tech is Fast-Tracking the Future of Medicine

by Dr. Josep Bassaganya-Riera | Sep 10, 2024 | Press Release

An original version of this article appeared in the Pharmaceutical Executive. The AI revolution is shaping numerous facets of our lives. While advancements by OpenAI and Anthropic plus NVIDIA’s market performance have commanded a significant portion of media...

NImmune Biopharma Announces R&D Collaboration with BioTherapeutics, Inc. to Advance the Next Wave of Inflammation and Immunology Precision Medicines

by NImmune Biopharma | Sep 5, 2024 | Press Release

Download Press Release NImmune will leverage BioTherapeutics’ computational and preclinical services to accelerate biomarker-driven development of its LANCL immunoregulatory drug pipeline Growing scientific ecosystem also includes NIMML Institute’s TITAN-X...

NImmune Biopharma Presents Positive First-in-Human Data of NIM-1324, a Phase 2 Candidate for Systemic Lupus Erythematosus at the American College of Rheumatology Convergence 2023 (#ACR23)

by NImmune Biopharma | Nov 14, 2023 | Press Release

Download Press Release First-in-human clinical trial of NIM-1324 met all primary and secondary endpoints Daily oral treatment with NIM-1324 is well-tolerated and safe with no dose-limiting toxicities Oral treatment with NIM-1324 induces a dose-proportional change in...

NImmune Biopharma Announces Publication on the Safety, Efficacy and Novel LANCL2 Mechanism of Action of Omilancor in Inflammatory Bowel Diseases

by NImmune Biopharma | Nov 2, 2023 | Press Release

This publication describes novel LANCL2-based immunoregulatory mechanisms that enhance regulatory T cells (Tregs) anti-inflammatory functions by amplifying IL-2 signaling and promote T cell metabolic reprogramming resulting in enhanced mitochondrial metabolism...